Glutathione-responsive exosome bionic dendrimer nanogel vaccine as well as preparation method and application thereof

By preparing a glutathione-responsive exosome-inspired dendritic macromolecular nanogel vaccine loaded with 5-azacytidine and R837, the problems of low antigen delivery efficiency and immunosuppression in tumor vaccines in the tumor microenvironment were solved, achieving tumor demethylation and synergistic immunotherapy, thus improving the therapeutic effect.

CN122440801APending Publication Date: 2026-07-24DONGHUA UNIV
0 Cites 0 Cited by

Patent Information

Application Number
CN202610891085.X
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2026-06-18
Publication Date
2026-07-24

AI Technical Summary

Technical Problem

Existing tumor vaccines suffer from problems such as low antigen delivery efficiency, severe immunosuppression in the tumor microenvironment, and ineffective regulation of epigenetic abnormalities in tumor treatment, resulting in limited therapeutic effects.

Method used

The exosome-inspired dendritic macromolecular nanogel vaccine, which is responsive to glutathione, is loaded with 5-azacytidine and imiquimod R837. It utilizes glutathione stimulation in the tumor microenvironment to achieve targeted drug release, activate antigen-presenting cells, reverse the immunosuppressive microenvironment, and achieve tumor demethylation and synergistic immunotherapy.

Benefits of technology

It significantly improves the antigen delivery efficiency of tumor vaccines, activates anti-tumor immune responses, improves the tumor microenvironment, and achieves precise, low-toxicity, and long-lasting treatment of pancreatic cancer.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

The invention relates to a glutathione responsive exosome bionic dendrimer nanogel vaccine as well as a preparation method and application thereof. The vaccine is prepared by taking dendrimer nanogel as a carrier, loading 5-Aza, coating tumor cells Ex and modifying R837 in sequence. The vaccine realizes precise tumor drug delivery by virtue of the homologous targeting characteristic of Ex, and can respond to high glutathione characteristic targeted drug release in a tumor microenvironment. Wherein 5-Aza plays an epigenetic treatment effect through DNA demethylation, and induces tumor cells to generate pyroptosis type ICD at the same time. The R837 immunologic adjuvant can cooperate with the tumor-associated antigen carried by Ex to promote the maturation of dendritic cells, promote the polarization of M2-type tumor-associated macrophages to M1-type macrophages, and reverse the tumor immunosuppression microenvironment. The epigenetic therapy and the immunotherapy are combined, a brand new strategy is provided for clinical treatment of pancreatic cancer, and the clinical application prospect is wide.
Need to check novelty before this filing date? Find Prior Art